Sonoma Pharmaceuticals, Inc. 8-K

What Happened
Sonoma Pharmaceuticals (SNOA) filed an 8‑K on Jan. 28, 2026 reporting that long‑time director Dr. Jay Birnbaum retired from the board effective January 28, 2026 and will continue for one year under a consulting agreement. The company also appointed Vanessa Jacoby as an independent director effective the same date; she was named Chair of the Audit Committee and a non‑chair member of the Compensation Committee.

Key Details

• Dr. Jay Birnbaum retired from the Board effective January 28, 2026 and will serve under a one‑year consulting agreement.
• Consulting pay to Dr. Birnbaum: 5,000 Restricted Stock Units (RSUs) representing 5,000 shares per quarter; these RSUs vest on the second business day after Sonoma files its Form 10‑K for the year ended March 31, 2027, or upon a change of control. Existing equity awards will continue to vest per their terms, subject to compliance with the consulting agreement.
• Board compensation plan amended (Jan. 28, 2026) to give the Board discretion on the number and form of annual and initial equity grants to non‑employee directors.
• Vanessa Jacoby appointment: effective Jan. 28, 2026; will receive annual retainer $32,500 plus $10,000 as Audit Committee Chair and $7,500 as a Compensation Committee member; reimbursed for meeting expenses. She received an automatic option grant to purchase 10,000 shares vesting in three equal annual installments (or upon change of control).
• Sonoma entered standard indemnification and director agreements with Ms. Jacoby consistent with prior company forms.

Why It Matters
This 8‑K signals a planned leadership transition at the board level: an experienced director retired while Sonoma replaced him with a financial executive who will lead the Audit Committee. For investors, material points are the potential share dilution from RSUs and option grants, the timing of vesting (notably the RSUs tied to the FY2027 Form 10‑K filing or change of control), and continuity of governance through indemnification and director agreements. The filing maintains that these changes are routine board governance actions and discloses compensation and equity arrangements that could affect outstanding share count and executive/board costs.